These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 31082343)
1. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis]. Feng BL; Yu HH; Shen W Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):304-311. PubMed ID: 31082343 [No Abstract] [Full Text] [Related]
3. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Yin Q; Li J; Xia Y; Zhang R; Wang J; Lu W; Zhou Y; Zheng Y; Abudumijiti H; Chen R; Chen K; Li S; Liu T; Wang F; Lu J; Zhou Y; Guo C Drug Des Devel Ther; 2015; 9():5407-19. PubMed ID: 26491252 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis. Khakoo NS; Sultan S; Reynolds JM; Levy C Dig Dis Sci; 2023 Apr; 68(4):1559-1573. PubMed ID: 36180756 [TBL] [Abstract][Full Text] [Related]
5. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate. Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185 [TBL] [Abstract][Full Text] [Related]
6. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Reig A; Sesé P; Parés A Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567 [TBL] [Abstract][Full Text] [Related]
7. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis. Lin W; Wang JX; Liu YJ Syst Rev; 2024 Jan; 13(1):46. PubMed ID: 38287391 [TBL] [Abstract][Full Text] [Related]
8. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675 [TBL] [Abstract][Full Text] [Related]
9. Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis. Shen N; Pan J; Miao H; Zhang H; Xing L; Yu X Ann Palliat Med; 2021 Jul; 10(7):7697-7705. PubMed ID: 34353058 [TBL] [Abstract][Full Text] [Related]
10. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up. Sorda JA; González Ballerga E; Barreyro FJ; Avagnina A; Carballo P; Paes de Lima A; Daruich J Aliment Pharmacol Ther; 2021 Nov; 54(9):1202-1212. PubMed ID: 34587309 [TBL] [Abstract][Full Text] [Related]
12. Additional fibrate treatment in UDCA-refractory PBC patients. Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis. Zhang H; Li S; Feng Y; Zhang Q; Xie B Clin Exp Med; 2023 Sep; 23(5):1741-1749. PubMed ID: 36318376 [TBL] [Abstract][Full Text] [Related]
14. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624 [TBL] [Abstract][Full Text] [Related]
15. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. Hazzan R; Tur-Kaspa R J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis. Wang ZL; Song KM; Jin R; Xie YD; Wang YQ; Liu ZC; Feng B Medicine (Baltimore); 2022 Mar; 101(9):e28987. PubMed ID: 35244071 [TBL] [Abstract][Full Text] [Related]
17. Bezafibrate treatment: a new medical approach for PBC patients? Kanda T; Yokosuka O; Imazeki F; Saisho H J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134 [TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid for primary biliary cirrhosis. Gong Y; Huang ZB; Christensen E; Gluud C Cochrane Database Syst Rev; 2008 Jul; (3):CD000551. PubMed ID: 18677775 [TBL] [Abstract][Full Text] [Related]
19. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Lens S; Leoz M; Nazal L; Bruguera M; Parés A Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. Zhang Y; Li S; He L; Wang F; Chen K; Li J; Liu T; Zheng Y; Wang J; Lu W; Zhou Y; Yin Q; Xia Y; Zhou Y; Lu J; Guo C Drug Des Devel Ther; 2015; 9():2757-66. PubMed ID: 26045661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]